纤溶酶原激活物抑制剂-1与糖尿病足发病关系的研究

Relationship between plasminogen activator inhibitor-1 and diabetic foot

目的:探讨纤溶酶原激活物抑制剂-1(PAI-1)与糖尿病足(DF)发病的关系,为DF的防治提供依据。方法:42例DF患者为DF组,38例糖尿病(DM)无DF患者为DMNDF组,45名体检健康者为对照组,比较3组间PAI-1、糖基化血红蛋白(HbA1c)、C反应蛋白(CRP)等指标水平的变化。结果:对照组、DMNDF组、DF组PAI-1、HbA1c、CRP依次升高,且差异均有统计学意义(P<0.05～P<0.01)。结论:DF患者PAI-1水平较高;对2型DM患者进行积极干预治疗,降低PAI-1水平,提高纤溶活性,可能延缓动脉硬化、狭窄,减少DF的发生。

Objective： To investigate the correlation between plasminogen activator inhibitor-1 （ PAI-1 ） and diabetic foot, and to provide references for the prevention and treatment of diabetic foot （DF）. Methods：Forty-two patients with DF were included in the DF group, 38 diabetes mellitus（DM） with non-DF were DMNDF group, and 45 volunteers were selected as control. The plasma concentration of PAI-1, glycosylated hemoglobin （ HbAlc ） and C reactive protein （CRP） were compared among the groups. Results： There were statistically significant differences among the DF group, control group and DMNDF groups in PAI-1, HbAlc and CRP（ P 〈 O. 05 -P 〈 0.01 ）. Conclusions ： PAI-1 is obviously correlated with the DF. Active interference and therapy for type 2 DM could decrease the PAI- l, increase the fibrinolytic activity and inhibit the progression of atherosclerosis, thus reducing the incidence of the DF.